Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price Target & Predictions
AUPH Stock Forecast
Aurinia Pharmaceuticals stock forecast is as follows: an average price target of $10.75 (represents a 49.10% upside from AUPH’s last price of $7.21) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
AUPH Price Target
The average price target for Aurinia Pharmaceuticals (AUPH) is $10.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $6.00. This represents a potential 49.10% upside from AUPH's last price of $7.21.
AUPH Analyst Ratings
According to 4 Wall Street analysts, Aurinia Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AUPH stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aurinia Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 06, 2024 | Ed Arce | H.C. Wainwright | $13.00 | $6.91 | 88.13% | 80.31% |
| May 02, 2024 | Maury Raycroft | Jefferies | $6.00 | $5.10 | 17.65% | -16.78% |
| Jan 04, 2023 | - | RBC Capital | $11.00 | $5.94 | 85.19% | 52.57% |
| Aug 09, 2022 | - | H.C. Wainwright | $26.00 | $8.27 | 214.39% | 260.61% |
| Aug 08, 2022 | - | Oppenheimer | $13.00 | $8.37 | 55.32% | 80.31% |
| May 05, 2022 | - | H.C. Wainwright | $30.00 | $11.37 | 163.85% | 316.09% |
| Apr 28, 2022 | - | RBC Capital | $22.00 | $10.41 | 111.34% | 205.13% |
The latest Aurinia Pharmaceuticals stock forecast, released on Sep 06, 2024 by Ed Arce from H.C. Wainwright, set a price target of $13.00, which represents a 88.13% increase from the stock price at the time of the forecast ($6.91), and a 80.31% increase from AUPH last price ($7.21).
Aurinia Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $13.00 | $9.50 |
| Last Closing Price | $7.21 | $7.21 | $7.21 |
| Upside/Downside | -100.00% | 80.31% | 31.76% |
In the current month, the average price target of Aurinia Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aurinia Pharmaceuticals's last price of $7.21. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 02, 2024 | Jefferies | Hold | Hold | Hold |
| Jan 04, 2023 | RBC Capital | Outperform | Outperform | Hold |
| Aug 08, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Apr 28, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Feb 23, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Dec 10, 2021 | Oppenheimer | - | Outperform | Upgrade |
Aurinia Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave AUPH a "Buy" rating, the same as its previous rate.
Aurinia Pharmaceuticals Financial Forecast
Aurinia Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $42.31M | $40.78M | $41.49M | $34.41M | $28.43M | $55.78M | $28.19M | $21.63M | $23.40M | $14.67M | $6.62M | $914.00K | $50.03M | $29.00K | $29.00K | $30.00K | $29.00K | $230.00K | $29.00K | $30.00K | $30.00K | $31.00K |
| Avg Forecast | $77.45M | $72.70M | $69.75M | $65.80M | $66.76M | $57.48M | $54.25M | $47.07M | $45.00M | $38.44M | $37.90M | $27.87M | $27.77M | $36.19M | $27.04M | $19.23M | $22.00M | $13.87M | $4.96M | $3.03M | $12.53M | $43.43K | $27.56K | $37.00K | $61.71K | $41.50K | $44.00K | $38.00K | $28.33K | $3.91K |
| High Forecast | $77.45M | $72.70M | $69.75M | $65.80M | $66.76M | $65.49M | $54.25M | $47.07M | $46.59M | $39.94M | $37.90M | $27.87M | $27.77M | $36.19M | $27.04M | $19.23M | $22.00M | $13.87M | $4.96M | $3.03M | $12.53M | $43.43K | $27.56K | $37.00K | $61.71K | $41.50K | $44.00K | $38.00K | $34.00K | $4.69K |
| Low Forecast | $77.45M | $72.70M | $69.75M | $65.80M | $66.76M | $54.50M | $54.25M | $47.07M | $42.54M | $36.44M | $37.90M | $27.87M | $27.77M | $36.19M | $27.04M | $19.23M | $22.00M | $13.87M | $4.96M | $3.03M | $12.53M | $43.43K | $27.56K | $37.00K | $61.71K | $41.50K | $44.00K | $38.00K | $22.66K | $3.13K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | 0.94% | 1.06% | 1.09% | 1.23% | 1.02% | 1.54% | 1.04% | 1.12% | 1.06% | 1.06% | 1.33% | 0.30% | 3.99% | 0.67% | 1.05% | 0.81% | 0.47% | 5.54% | 0.66% | 0.79% | 1.06% | 7.92% |
Aurinia Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $47.07M, with a low forecast of $47.07M, and a high forecast of $47.07M. AUPH's average Quarter revenue forecast represents a 11.25% increase compared to the company's last Quarter revenue of $42.31M (Dec 23).
Aurinia Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | $-29.67M | $-16.26M | $-11.35M | $-29.58M | $-28.10M | $-8.69M | $-35.15M | $-37.04M | $-31.80M | $-49.46M | $-46.15M | $-49.51M | $-22.09M | $-33.50M | $-28.93M | $-16.34M | $-75.99M | $-18.61M | $-15.38M | $-12.02M | $-14.84M | $-51.50M |
| Avg Forecast | $-65.68M | $-61.65M | $-59.15M | $-55.80M | $-56.62M | $-48.74M | $-46.01M | $-44.19M | $-38.16M | $-32.60M | $-32.14M | $-40.17M | $-32.04M | $-30.69M | $-22.93M | $-36.52M | $-18.65M | $-11.76M | $-4.21M | $-44.16M | $-10.63M | $-36.83K | $-23.37K | $-21.24M | $-52.33K | $-35.19K | $-37.31K | $-12.82M | $-14.19M | $-263.05M |
| High Forecast | $-65.68M | $-61.65M | $-59.15M | $-55.80M | $-56.62M | $-46.22M | $-46.01M | $-35.35M | $-36.08M | $-30.90M | $-32.14M | $-32.14M | $-25.64M | $-30.69M | $-22.93M | $-29.22M | $-18.65M | $-11.76M | $-4.21M | $-35.33M | $-10.63M | $-36.83K | $-23.37K | $-17.00M | $-52.33K | $-35.19K | $-37.31K | $-10.26M | $-11.35M | $-210.44M |
| Low Forecast | $-65.68M | $-61.65M | $-59.15M | $-55.80M | $-56.62M | $-55.53M | $-46.01M | $-53.03M | $-39.51M | $-33.87M | $-32.14M | $-48.21M | $-38.45M | $-30.69M | $-22.93M | $-43.82M | $-18.65M | $-11.76M | $-4.21M | $-53.00M | $-10.63M | $-36.83K | $-23.37K | $-25.49M | $-52.33K | $-35.19K | $-37.31K | $-15.39M | $-17.03M | $-315.66M |
| Surprise % | - | - | - | - | - | - | - | - | 0.78% | 0.50% | 0.35% | 0.74% | 0.88% | 0.28% | 1.53% | 1.01% | 1.70% | 4.21% | 10.97% | 1.12% | 2.08% | 909.55% | 1238.20% | 0.77% | 1452.05% | 528.94% | 412.13% | 0.94% | 1.05% | 0.20% |
undefined analysts predict AUPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aurinia Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Aurinia Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| Net Income | - | - | - | - | - | - | - | - | $-26.88M | $-13.45M | $-11.49M | $-26.21M | $-26.05M | $-8.99M | $-35.52M | $-37.63M | $-33.32M | $-50.26M | $-47.01M | $-50.38M | $-22.56M | $-34.06M | $-29.53M | $-16.53M | $-76.48M | $-19.04M | $-15.90M | $-12.43M | $-15.48M | $-51.94M |
| Avg Forecast | $19.45M | $15.85M | $14.41M | $12.25M | $13.69M | $2.16M | $1.20M | $-45.53M | $-23.54M | $-24.09M | $-26.42M | $-41.39M | $-33.46M | $-33.43M | $-31.91M | $-37.63M | $-38.70M | $-47.97M | $-52.60M | $-44.78M | $-28.46M | $-33.56M | $-33.31M | $-21.49M | $-29.03M | $-27.14M | $-22.77M | $-13.26M | $-14.57M | $-264.90M |
| High Forecast | $19.45M | $15.85M | $14.41M | $12.25M | $13.69M | $4.32M | $1.22M | $-36.43M | $-18.31M | $-18.42M | $-26.42M | $-33.11M | $-26.77M | $-33.43M | $-31.91M | $-30.10M | $-38.70M | $-47.97M | $-52.60M | $-35.83M | $-28.46M | $-33.56M | $-33.31M | $-17.20M | $-29.03M | $-27.14M | $-22.77M | $-10.61M | $-11.65M | $-211.92M |
| Low Forecast | $19.45M | $15.85M | $14.41M | $12.25M | $13.69M | $1.08M | $1.18M | $-54.64M | $-31.38M | $-26.92M | $-26.42M | $-49.67M | $-40.16M | $-33.43M | $-31.91M | $-45.16M | $-38.70M | $-47.97M | $-52.60M | $-53.74M | $-28.46M | $-33.56M | $-33.31M | $-25.79M | $-29.03M | $-27.14M | $-22.77M | $-15.91M | $-17.48M | $-317.88M |
| Surprise % | - | - | - | - | - | - | - | - | 1.14% | 0.56% | 0.43% | 0.63% | 0.78% | 0.27% | 1.11% | 1.00% | 0.86% | 1.05% | 0.89% | 1.13% | 0.79% | 1.02% | 0.89% | 0.77% | 2.63% | 0.70% | 0.70% | 0.94% | 1.06% | 0.20% |
Aurinia Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aurinia Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| SG&A | - | - | - | - | - | - | - | - | $50.07M | $47.76M | $47.08M | $50.12M | $47.47M | $52.17M | $51.53M | $45.20M | $44.24M | $44.13M | $43.79M | $39.28M | $38.31M | $31.07M | $15.54M | $11.06M | $7.25M | $6.06M | $4.95M | $3.90M | $3.79M | $3.43M |
| Avg Forecast | $1.21B | $1.13B | $1.09B | $1.03B | $1.04B | $895.75M | $845.44M | $733.58M | $701.26M | $599.00M | $590.57M | $434.38M | $432.81M | $563.90M | $421.42M | $299.68M | $342.76M | $216.13M | $77.30M | $47.19M | $195.34M | $676.77K | $429.42K | $576.59K | $961.72K | $646.71K | $685.67K | $592.17K | $441.53K | $60.98K |
| High Forecast | $1.21B | $1.13B | $1.09B | $1.03B | $1.04B | $1.02B | $845.45M | $733.59M | $726.05M | $622.34M | $590.57M | $434.38M | $432.81M | $563.90M | $421.42M | $299.68M | $342.76M | $216.13M | $77.30M | $47.19M | $195.34M | $676.77K | $429.42K | $576.59K | $961.72K | $646.71K | $685.67K | $592.17K | $529.81K | $73.15K |
| Low Forecast | $1.21B | $1.13B | $1.09B | $1.03B | $1.04B | $849.34M | $845.44M | $733.58M | $662.94M | $567.89M | $590.57M | $434.38M | $432.81M | $563.90M | $421.42M | $299.68M | $342.76M | $216.13M | $77.30M | $47.19M | $195.34M | $676.77K | $429.42K | $576.59K | $961.72K | $646.71K | $685.67K | $592.17K | $353.20K | $48.76K |
| Surprise % | - | - | - | - | - | - | - | - | 0.07% | 0.08% | 0.08% | 0.12% | 0.11% | 0.09% | 0.12% | 0.15% | 0.13% | 0.20% | 0.57% | 0.83% | 0.20% | 45.91% | 36.19% | 19.18% | 7.53% | 9.37% | 7.21% | 6.59% | 8.59% | 56.20% |
Aurinia Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $733.58M, based on 1 Wall Street analysts, with a range of $733.58M to $733.59M. The forecast indicates a 1365.06% rise compared to AUPH last annual SG&A of $50.07M (Dec 23).
Aurinia Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| EPS | - | - | - | - | - | - | - | - | $-0.19 | $-0.09 | $-0.08 | $-0.18 | $-0.18 | $-0.06 | $-0.25 | $-0.27 | $-0.25 | $-0.39 | $-0.37 | $-0.40 | $-0.05 | $-0.28 | $-0.26 | $-0.15 | $-0.78 | $-0.21 | $-0.17 | $-0.14 | $-0.18 | $-0.92 |
| Avg Forecast | $0.14 | $0.11 | $0.10 | $0.09 | $0.10 | $0.01 | $0.01 | $-0.14 | $-0.16 | $-0.17 | $-0.18 | $-0.22 | $-0.27 | $-0.23 | $-0.22 | $-0.27 | $-0.27 | $-0.33 | $-0.36 | $-0.37 | $-0.20 | $-0.23 | $-0.23 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.15 | $-0.16 | $-0.61 |
| High Forecast | $0.14 | $0.11 | $0.10 | $0.09 | $0.10 | $0.03 | $0.01 | $-0.14 | $-0.13 | $-0.13 | $-0.18 | $-0.22 | $-0.27 | $-0.23 | $-0.22 | $-0.27 | $-0.27 | $-0.33 | $-0.36 | $-0.37 | $-0.20 | $-0.23 | $-0.23 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.15 | $-0.13 | $-0.49 |
| Low Forecast | $0.14 | $0.11 | $0.10 | $0.09 | $0.10 | $0.01 | $0.01 | $-0.14 | $-0.22 | $-0.19 | $-0.18 | $-0.22 | $-0.27 | $-0.23 | $-0.22 | $-0.27 | $-0.27 | $-0.33 | $-0.36 | $-0.37 | $-0.20 | $-0.23 | $-0.23 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.15 | $-0.19 | $-0.73 |
| Surprise % | - | - | - | - | - | - | - | - | 1.16% | 0.56% | 0.44% | 0.81% | 0.67% | 0.27% | 1.13% | 1.01% | 0.93% | 1.17% | 1.01% | 1.08% | 0.25% | 1.20% | 1.13% | 0.78% | 3.87% | 1.12% | 1.08% | 0.96% | 1.13% | 1.51% |
According to undefined Wall Street analysts, Aurinia Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUPH previous annual EPS of $NaN (undefined).
Aurinia Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| BTAI | BioXcel Therapeutics | $0.64 | $12.00 | 1775.00% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| MCRB | Seres Therapeutics | $0.81 | $1.25 | 54.32% | Buy |
| AUPH | Aurinia Pharmaceuticals | $7.21 | $10.75 | 49.10% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| SRPT | Sarepta Therapeutics | $123.07 | $169.63 | 37.83% | Buy |
| AXSM | Axsome Therapeutics | $87.25 | $117.83 | 35.05% | Buy |
| PTCT | PTC Therapeutics | $40.39 | $46.50 | 15.13% | Hold |
| TGTX | TG Therapeutics | $24.36 | $26.40 | 8.37% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| EXEL | Exelixis | $34.29 | $30.50 | -11.05% | Buy |
AUPH Forecast FAQ
Is Aurinia Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, Aurinia Pharmaceuticals (AUPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of AUPH's total ratings.
What is AUPH's price target?
Aurinia Pharmaceuticals (AUPH) average price target is $10.75 with a range of $6 to $13, implying a 49.10% from its last price of $7.21. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aurinia Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AUPH stock, the company can go up by 49.10% (from the last price of $7.21 to the average price target of $10.75), up by 80.31% based on the highest stock price target, and down by -16.78% based on the lowest stock price target.
Can Aurinia Pharmaceuticals stock reach $11?
AUPH's highest twelve months analyst stock price target of $13 supports the claim that Aurinia Pharmaceuticals can reach $11 in the near future.
What are Aurinia Pharmaceuticals's analysts' financial forecasts?
Aurinia Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $225.57M (high $233.58M, low $222.59M), average EBITDA is $-196M (high $-184M, low $-211M), average net income is $-28.479M (high $-17.187M, low $-38.691M), average SG&A $3.52B (high $3.64B, low $3.47B), and average EPS is $-0.0183 (high $-0.00317, low $-0.026). AUPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $285.7M (high $285.7M, low $285.7M), average EBITDA is $-242M (high $-242M, low $-242M), average net income is $61.97M (high $61.97M, low $61.97M), average SG&A $4.45B (high $4.45B, low $4.45B), and average EPS is $0.43 (high $0.43, low $0.43).
Did the AUPH's actual financial results beat the analysts' financial forecasts?
Based on Aurinia Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $158.53M, beating the average analysts forecast of $149.21M by 6.25%. Apple's EBITDA was $-91.691M, missing the average prediction of $-143M by -35.91%. The company's net income was $-78.02M, missing the average estimation of $-115M by -32.41%. Apple's SG&A was $195.04M, missing the average forecast of $2.33B by -91.61%. Lastly, the company's EPS was $-0.54, missing the average prediction of $-0.735 by -26.55%. In terms of the last quarterly report (Dec 2023), Aurinia Pharmaceuticals's revenue was $42.32M, missing the average analysts' forecast of $45M by -5.97%. The company's EBITDA was $-29.674M, missing the average prediction of $-38.16M by -22.24%. Aurinia Pharmaceuticals's net income was $-26.875M, beating the average estimation of $-23.537M by 14.18%. The company's SG&A was $50.07M, missing the average forecast of $701.26M by -92.86%. Lastly, the company's EPS was $-0.19, beating the average prediction of $-0.163 by 16.33%